University of California

Merck Sharp + Dohme Corp.

The University of North Carolina at Chapel Hill

Cold Spring Harbor Laboratory

The University of North Carolina

Lin He

Gregory J Hannon

Xingyue He

Peter S Linsley

Amy E Herr

Scott William Lowe

Lee Lim

Julja Burchard

Scott Hammond

Aimee L Jackson

Michele A Cleary

Jill F Magnus

Chao-Po Lin

John Michael Thomson

Summer Goodson

Yong Jin Choi

Andrew J Modzelewski

Elisabet Rosàs-Canyelles

Dual nucleic acid and protein isoform measurements are performed on low starting cell numbers (e.g. equivalent to the number of blastomeres composing early embryonic development stages (morula and blastocysts)), comprising integrating fractionation polyacrylamide gel electrophoresis (fPAGE) of 10-100 cells with off-chip analysis of nucleic acids in the nuclei.

Simultaneous detection of protein isoforms and nucleic acids from low starting cell numbers

The present disclosure provides a method of generating an induced pluripotent stem cell; as well as nucleic acids and genetically modified host cells useful in generating iPSCs. The present disclosure provides iPSCs, and methods of use of same.

Compositions and methods for generating induced pluripotent stem cells

In one aspect, the invention generally relates to use of miR-34 as a biomarker to estimate TP53 function in a cell. In another aspect, the invention generally relates to multiple uses of miR-34 and siRNAs functionally and structurally related to miR-34 for the treatment of cancer.

Methods of using MIR34 as a biomarker for TP53 functional status

The application relates to methods and compositions for the diagnosis, prevention, and treatment of tumors and cancers in mammals, for example, humans, utilizing the mir17-92 cluster. The application further relates to screening methods to identify compounds and reagents useful in cancer diagnosis, prevention, and therapy.

Compositions and methods for cancer diagnosis and treatment

Growing community of inventors

Berkeley, CA, United States of America

Lin He